Mike Garrison to Retire from BD

Rhea-AI Summary

BD (NYSE: BDX) announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, intends to retire after more than 20 years with the company, effective Oct. 2. Garrison has led multiple major businesses at BD, including the Medical segment, Medication Management Solutions and Surgery.

He will remain in his current role through the end of the fiscal year. BD has launched a comprehensive search for the next president of Medical Essentials, while BioPharma Systems will begin reporting directly to Chairman, CEO and President Tom Polen, reflecting its strategic role as a growth driver and streamlining BD’s operating model.

Positive

• Orderly leadership transition with retirement effective Oct. 2 and service through fiscal year-end
• BioPharma Systems to report directly to CEO, emphasizing growth focus and streamlined model

Negative

• Departure of long-tenured executive who led key segments, including Medical Essentials and BioPharma Systems

Market Context

Recent insider activity was Net Selling, with 5,188 shares sold and none bought over 90 days. That r...

Analysis

Recent insider activity was Net Selling, with 5,188 shares sold and none bought over 90 days. That record adds governance context to the retirement and succession search; investors can watch execution under the revised reporting structure.

Key Figures

BD tenure: more than 20 years Retirement effective date: Oct. 2 Employees: more than 60,000 employees +1 more

4 metrics

BD tenure more than 20 years Mike Garrison's tenure at BD

Retirement effective date Oct. 2 Mike Garrison's planned retirement

Employees more than 60,000 employees BD company description

Products delivered annually billions of products annually BD company description

Historical Context

5 past events · Latest: Jul 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 09	Earnings scheduling notice	Neutral	+0.7%	Management scheduled the fiscal third-quarter results webcast and operations update.
Jun 23	Contract award	Positive	+2.3%	Vizient awarded BD's CentroVena One insertion system an Innovative Technology contract.
May 21	Product launch	Positive	-0.5%	BD introduced the Elyra Thulium Fiber Laser System for urology procedures.
May 18	Leadership appointment	Positive	-0.8%	Peter Menziuso was appointed EVP and president of BD Interventional.
May 07	CFO appointment	Positive	+5.9%	Vitor Roque was named executive vice president and chief financial officer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BDX's recent news reactions were mixed, with positive moves following the earnings-date notice, contract award, and CFO appointment but negative moves after the product launch and leadership appointment.

Key Terms

r&d, pure-play

2 terms

r&d technical

"roles across R&D and marketing within the MedTech industry"

Research and development (R&D) is the work a company does to discover new products, improve existing ones, or develop better ways of making things — like a kitchen testing recipes to create a hit dish. For investors it matters because R&D is where future sales and competitive advantages are born, but it also uses cash and carries risk, so R&D spending and outcomes signal a company’s growth potential and uncertainty.

pure-play financial

"one of the world's largest pure-play medical technology companies"

A pure-play company focuses almost entirely on a single product, service, or market rather than operating across many different lines. For investors, that makes the company’s performance a direct bet on one specific business — like backing a single-sport team instead of a multi-sport club — so returns can be clearer but also more volatile because there’s less built-in diversification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FRANKLIN LAKES, N.J., July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2.

Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD's Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. Prior to joining BD in 2005, Garrison held various roles across R&D and marketing within the MedTech industry.

"Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions," said Tom Polen, Chairman, CEO and President of BD. "He has built strong teams, developed exceptional leaders and helped position our business for the future. We are grateful for Mike's leadership, partnership and many contributions to BD, and we wish him well in his retirement."

Garrison will remain in his role through the end of the fiscal year. A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Polen, streamlining the operating model and reflecting the segment's strategic importance as a growth driver.

"It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world," Garrison said. "I will always value the people, purpose and impact that have made my time at BD so meaningful, and I look forward to seeing the company continue to advance the future of care."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

Contacts:
Media	Investors
Megan Dubrowski Senior Director, Executive Communications Megan.Dubrowski@bd.com	Shawn Bevec SVP, Investor Relations Investor_Relations@bd.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mike-garrison-to-retire-from-bd-302831520.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

When is Mike Garrison retiring from BD (NYSE: BDX) and what is his current role?

Mike Garrison plans to retire from BD effective Oct. 2. According to BD, he currently serves as executive vice president and president of the Medical Essentials and BioPharma Systems segments and will stay in his role through the end of the fiscal year.

How will BD (BDX) reorganize leadership of the BioPharma Systems segment after Mike Garrison retires?

After Mike Garrison’s retirement, BD will have BioPharma Systems report directly to Tom Polen. According to BD, this change is intended to streamline the operating model and reflect the segment’s strategic importance as a growth driver for the company.

What succession plans has BD (BDX) announced for the Medical Essentials segment?

BD has started a comprehensive search to identify the next president of Medical Essentials. According to BD, Garrison will remain in his role through the fiscal year-end while the company evaluates candidates to ensure continuity and leadership stability in this core business.

How long has Mike Garrison worked at BD (NYSE: BDX) and what positions has he held?

Mike Garrison has spent more than 20 years at BD. According to BD, he has served as executive vice president and president of the Medical segment, worldwide president of Medication Management Solutions, worldwide president of Surgery, and most recently led Medical Essentials and BioPharma Systems.

Why is the leadership change in BD’s BioPharma Systems segment important for BDX investors?

The leadership change highlights BioPharma Systems as a strategic growth driver. According to BD, having this segment report directly to Chairman, CEO and President Tom Polen is intended to streamline the operating model and underscore its importance within the company’s long-term growth priorities.

What did BD’s CEO say about Mike Garrison’s impact on the company?

Tom Polen credited Mike Garrison with guiding BD through transformational periods. According to BD, Polen highlighted Garrison’s role in building strong teams, developing leaders and keeping customers, patients and associates central to decisions, which helped position BD’s businesses for the future.